How to Buy Intellia Therapeutics Stock
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. , a genome editing company, focuses on the development of therapeutics.
Intellia Therapeutics stock last closed at $21.17, down 1.67% from the previous day, and has decreased 42.02% in one year. It has underperformed other stocks in the Biotechnology industry by 0.18 percentage points. Intellia Therapeutics stock is currently +1.88% from its 52-week low of $20.78, and -55.41% from its 52-week high of $47.48.
As of Apr 24, 2024, there are 96.11M NTLA shares outstanding. The market capitalization of NTLA is $2.03B. In the past 24 hours, 858,121 NTLA shares were traded.
How to Buy Intellia Therapeutics Stock
Not sure how to invest in Intellia Therapeutics stock? Here's how.
- Figure out where to buy Intellia Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Intellia Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Pick your method of payment and add your info.
- Evaluate Intellia Therapeutics stock: The Intellia Therapeutics ticker symbol is NTLA. Is Intellia Therapeutics stock a good investment? Should you buy shares of NTLA? How do NTLA's underlying business fundamentals look? Do top analysts think Intellia Therapeutics is a good buy? Why has NTLA's stock price moved recently? (Hint: Our stock analysis website can help you figure out if NTLA is a good stock to buy).
- Execute your NTLA purchase: Decide if you will purchase NTLA shares at the current market price or use a limit order to purchase NTLA shares at a particular price.
- Watch your investment in NTLA: Create a watchlist to key updates about your new investment in Intellia Therapeutics shares.
Step 1: Figure out where to buy Intellia Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy NTLA stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Technology to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro now.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal info so you are able to invest in NTLA stock today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to open a new trading account.
- Send your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have created your account on app for stock, you need to deposit funds:
Watch this video walkthrough to see the process of transferring funds into your investment account.
Step 4: Evaluate Intellia Therapeutics stock
Once you have selected the best place to buy Intellia Therapeutics stock, it's critical to analyze their stock before you buy, so you actually understand the risk as well as the opportunity.
Intellia Therapeutics stock at a glance
NTLA Fundamentals
WallStreetZen was created to help average investors do more accurate fundamental analysis.
You can see all of the due diligence checks on NTLA's stock page.
Is NTLA stock properly valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge NTLA's fair value.
Using relative valuations methods:
- NTLA may be undervalued based on its P/B ratio of 1.94x, relative to Biotechnology industry P/B ratio of 5.86x
You can do more valuation research on NTLA's stock here.
NTLA Financial Health Summary
Positive Financial Indicators:
- NTLA has cash burn of 408071000. It has enough cash and short-term investments to cover this for at least one year.
- NTLA has a low debt to equity ratio of 0.24.
- There are more short-term assets than long-term liabilities on the NTLA balance sheet.
- There are more short-term assets than short-term liabilities on the NTLA balance sheet.
- Total NTLA debt is lower than 5 years ago, relative to shareholder equity.
Negative Financial Indicators:
- NTLA profit margin has gone down from -909.8% to -1,326.5% in the past year.
- NTLA has $912.22M in cash and short term investments. This is not sufficient to cover its annual cash burn of $408.07M.
Do Wall Street analysts think it's a good time to buy NTLA stock
Out of 8 sell side analysts who give forecasts on NTLA, the consensus analyst rating on Intellia Therapeutics is a Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Most Recent NTLA Analyst Forecasts
Kostas Biliouris, a bottom 4% analyst from BMO Capital maintains NTLA with a buy rating and lowers their NTLA price target from $64.00 to $62.00, on Nov 10, 2023.
Luca Issi, a bottom 4% analyst from RBC Capital maintains NTLA with a buy rating and lowers their NTLA price target from $80.00 to $70.00, on Nov 10, 2023.
Steven Seedhouse, a top 11% analyst from Raymond James maintains NTLA with a buy rating and lowers their NTLA price target from $78.00 to $57.00, on Nov 10, 2023.
You can dig deeper into what analysts are projecting on the Intellia Therapeutics stock forecast page.
NTLA Momentum
NTLA Revenue
Last year, NTLA revenue was $36.28M. Over the last 5 year, NTLA's revenue has gone up by 3.57% per year. This was slower than the Biotechnology industry average of 28.91%.
Find out more about NTLA's earnings and revenue performance here.
What are NTLA executives and large shareholders up to?
Over the last year, executives and large shareholders at NTLA have sold more shares than they have bought.
James Basta, EVP General Counsel of NTLA, was the latest NTLA insider to sell. They sold $75,778.03 worth of NTLA stock on Mar 4, 2024.
Get more info about who owns NTLA shares here.
Does NTLA stock generate passive income?
No, Intellia Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about NTLA
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your NTLA purchase
There are two main options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount limit, use a limit order.
Click the Open button and eToro will place your order.
If you want more help buying stocks on eToro, click the how to video below:
Step 6: Watch your investment in NTLA
Now that you own some shares in NTLA, you'll want to keep up with your new investment.
Put NTLA on a watchlist to track the latest developments regarding your NTLA stock.
NTLA Feed
How to Buy Stock in Intellia Therapeutics
To summarize, here are the 6 steps for buying Intellia Therapeutics stock:
- Figure out where to buy Intellia Therapeutics stock
- Open a brokerage account
- Fund your brokerage account
- Evaluate Intellia Therapeutics stock
- Execute your NTLA purchase
- Watch your investment in NTLA
If you are looking for a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to track your investment in Intellia Therapeutics, create a watchlist today.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.